|
(11) | EP 3 119 756 B9 |
| (12) | CORRECTED EUROPEAN PATENT SPECIFICATION |
| Note: Bibliography reflects the latest situation |
|
|
| (54) |
2-(2,4-DIFLUOROPHENYL)-1,1-DIFLUORO-1-(5-SUBSTITUTED-PYRIDIN-2-YL)-3-(1H-TETRAZOL-1-YL)PROPAN-2-OLS AND PROCESSES FOR THEIR PREPARATION 2-(2,4-DIFLUORPHENYL)-1,1-DIFLUOR-1-(5-SUBSTITUTIERTES-PYRIDIN-2-YL)-3-(1H-TETRAZOL-1-YL)PROPAN-2-OLE UND VERFAHREN ZU DEREN HERSTELLUNG 2-(2,4-DIFLUOROPHÉNYL)-1,1-DIFLUORO-1-(5-SUBSTITUTION-PYRIDINE-2-YL)-3-(1H-TETRAZOL-1-YL)PROPANE-2-OLES ET PROCÉDÉS DE PRÉPARATION CORRESPONDANTS |
|
|
|||||||||||||||||||||||||||||||
| Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention). |
FIELD
BACKGROUND
SUMMARY OF THE DISCLOSURE
DETAILED DESCRIPTION
Example 1: Preparation of 4-((6-bromopyridin-3-yl)oxy)benzonitrile (1)
| Compound No. | R1 | Appearance | Prepared as in Example(s): | R2-F |
| 1 |
|
Brown solid | Ex 1, Methods A and B |
|
| 2 |
|
Off-white solid | Ex 1, Method B |
|
| 3 |
|
White Solid | Ex 1, Method B |
|
| Compound No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 1 | 113 | 275 ([M]+) | 8.22 (d, J = 2.9 Hz, 1H), 7.70 - 7.63 (m, 2H), 7.56 - 7.51 (m, 1H), 7.28 (dd, J = 8.5, 2.9 Hz, 1H), 7.10 - 7.02 (m, 2H) | ||
| 2 | 8.39 - 8.32 (m, 1H), 8.27 - 8.22 (m, 1H), 7.97 - 7.85 (m, 1H), 7.49 (dd, J = 8.6, 0.5 Hz, 1H), 7.41 (dd, J = 8.6, 2.9 Hz, 1H), 7.09 (d, J = 8.7 Hz, 1H) | 13C NMR (101 MHz, CDCl3) δ 164.46 (s), 149.27 (s), 145.02 (q, J = 4.3 Hz), 143.88 (s), 139.03 - 134.92 (m), 132.18 (s), 128.54 (s), 124.81 (s), 122.54 (q, J = 33.3 Hz), 122.12 (s), 111.83 (s) | |||
| 3 | 284 ([M]+) | 8.27 (dd, J = 3.0, 0.6 Hz, 1H), 8.08 (dd, J = 2.7, 0.7 Hz, 1H), 7.71 (dd, J = 8.7, 2.6 Hz, 1H), 7.51 (dd, J = 8.6, 0.6 Hz, 1H), 7.41 (dd, J = 8.6, 2.9 Hz, 1H), 6.98 (dd, J = 8.7, 0.7 Hz, 1H) |
| a All 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 2. Preparation of 2-bromo-5-(2,2,2-trifluoroethoxy)pyridine
Example 3: Preparation of ethyl 2-(5-(4-cyanophenoxy)pyridin-2-yl)-2,2-difluoroacetate (5)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 5 |
|
Brown oil | Ex 3, Methods A and B |
| 6 |
|
Amber oil | Ex 3, Method B |
| 7 |
|
Colorless oil | Ex 3, Method B |
| 8 |
|
Brown oil | Ex 3, Method B |
| 9 | Br | ClearColorless oil | Ex 3, Method A |
| 10 |
|
Yellow oil | Ex 3, Method B |
| Compound No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 5 | 319 ([M+H]+) | (300 MHz, CDCl3) δ 8.44 (d, J = 2.7 Hz, 1H), 7.78 (d, J = 8.7 Hz, 1H), 7.73 - 7.64 (m, 2H), 7.49 (dd, J = 8.6, 2.7 Hz, 1H), 7.16 - 7.07 (m, 2H), 4.39 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.2 Hz, 3H) | 2229, 1767 | ||
| 6 | 300 ([M+H]+) | 8.37 (dd, J = 2.9, 0.6 Hz, 1H), 7.72 (dd, J = 8.8, 0.7 Hz, 1H), 7.39 (dd, J = 8.7, 2.9 Hz, 1H), 4.46 (q, J = 7.9 Hz, 2H), 4.37 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H) | 19F NMR -73.82 (s, 3F), - 104.24 (s, 2F) | ||
| 7 | 363 ([M+H]+) | 8.54 (d, J = 2.5 Hz, 1H), 8.48 - 8.37 (m, 1H), 8.06 - 7.93 (m, 1H), 7.82 (dd, J = 8.6, 0.6 Hz, 1H), 7.72 (dd, J = 8.6, 2.6 Hz, 1H), 7.16 (d, J = 8.7 Hz, 1H), 4.40 (q, J = 7.1 Hz, 2H), 1.36 (t, J = 7.1 Hz, 3H) | |||
| 8 | 328 ([M]+) | 8.51 (dd, J = 2.7, 0.7 Hz, 1H), 8.10 (dd, J = 2.7, 0.7 Hz, 1H), 7.78 (dd, J = 8.7, 0.7 Hz, 1H), 7.67 (dd, J = 8.6, 2.6 Hz, 1H), 7.01 (dd, J = 8.7, 0.7 Hz, 1H), 4.39 (q, J = 7.1 Hz, 2H), 1.35 (t, J = 7.1 Hz, 3H) | |||
| 9 | 281 ([M+H]+) | 1H NMR (400 MHz, CDCl3) δ 8.71 (dd, J = 2.23, 0.57 Hz, 1H), 8.00 (dd, J = 8.4, 2.3 Hz, 1H), 7.65 (dd, J = 8.4, 0.7 Hz, 1H), 4.37 (q, J = 7.1 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H) | 19F NMR -105.2 (s) | ||
| 10 | 8.59 (s, 1H), 7.85 (dd, J = 8.2, 1.4 Hz, 1H), 7.76 (d, J = 8.1 Hz, 1H), 4.38 (q, J = 7.1 Hz, 2H), 3.48 (q, J = 10.5 Hz, 2H), 1.33 (t, J = 7.1 Hz, 3H) | 2990, 1768 |
| a All 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 4: Preparation of 2-(5-(4-cyanophenoxy)pyridin-2-yl)-2,2-difluoro-N-methoxy-N-methylacetamide (11)
| Comp ound No. | R1 | -N(R3)(R4) | Appearance | Prepared as in Example(s): |
| 11 |
|
-N(OCH3)(CH3) | Light yellow solid | Ex 4 |
| 12 |
|
-N(CH3)(CH3) | Oil | Ex 4 |
| 13 |
|
N(CH2CH3)(CH2 CH3) | Oil | Ex 4 |
| 14 |
|
|
Clear oil | Ex 4 |
| 15 |
|
-N(OCH3)(CH3) | Off-white solid | Ex 4 |
| 16 |
|
-N(OCH3)(CH3) | Light yellow solid | Ex 4 |
| 17 |
|
-N(OCH3)(CH3) | Yellow solid | Ex 4 |
| 18 |
|
-N(OCH3)(CH3) | Oil | Ex 4 |
| Compou nd No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 11 | 101 | 334 | 8.42 (d, J = 4.0 Hz, 1H), 7.71 (m, 3H), 7.49 (dd, J = 8.0, 4.0 Hz, 1H), 7.10 (m, 2H), 3.56 (s, 3H), 3.29 (s, 3H) | ||
| 12 | 319 | 8.45 (dd, J = 2.8, 0.7 Hz, 1H), 7.81-7.63 (m, 3H), 7.50 (dd, J = 8.6, 2.8 Hz, 1H), 7.18 -7.05 (m, 2H), 3.15 (t, J = 1.9 Hz, 3H), 3.07 (t, J = 0.8 Hz, 3H) | 19F NMR (376 MHz, CDCl3) δ -97.58 (s) | ||
| 13 | 346 | 8.45 (d, J = 4.0 Hz, 1H), 7.72 (m, 3H), 7.49 (dd, J = 12.0, 4.0 Hz, 1H), 7.10 (m, 2H), 3.47 (m, 4H), 1.20 (m, 6H) | 162.28, 159.65, 153.10, 148.85, 141.36, 134.53, 127.39, 122.22, 118.95, 118.23, 114.24, 107.89, 42.24, 41.73, 14.16, 12.27 | ||
| 14 | 359 | (300 MHz, CDCl3) δ 8.44 (d, J = 2.7 Hz, 1H), 7.76 (d, J = 8.6 Hz, 1H), 7.69 (m, 2H), 7.49 (dd, J = 8.7, 2.7 Hz, 1H), 7.11 (m, 2H), 3.70 (m, 8H) | |||
| 15 | 315 ([M+H]+) | 8.34 (d, J = 2.9 Hz, 1H), 7.68 (d, J = 8.8 Hz, 1H), 7.41 (dd, J = 8.7, 2.9 Hz, 1H), 4.46 (q, J = 7.9 Hz, 2H), 3.49 (s, 3H), 3.27 (s, 3H) | 19F NMR -73.79 (s, 3F), - 100.76 (s, 2F) | ||
| 16 | 378 ([M+H]+) | 8.52 (d, J = 2.4 Hz, 1H), 8.46 - 8.38 (m, 1H), 8.03 -7.94 (m, 1H), 7.78 (dd, J = 8.6, 0.4 Hz, 1H), 7.72 (dd, J = 8.6, 2.5 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 3.50 (s, 3H), 3.29 (s, 3H) | |||
| 17 | 343 ([M]+) | 8.49 (dd, J = 2.6, 0.8 Hz, 1H), 8.10 (dd, J = 2.6, 0.7 Hz, 1H), 7.78 - 7.70 (m, 2H), 7.67 (dd, J = 8.6, 2.6 Hz, 1H), 7.00 (dd, J = 8.7, 0.7 Hz, 1H), 3.50 (s, 3H), 3.29 (s, 3H) | |||
| 18 | 299 ([M+H]+) | 8.56 (s, 1H), 7.83 (dd, J = 8.1, 1.6 Hz, 1H), 7.71 (d, J = 7.9 Hz, 1H), 3.46 (m, 5H), 3.28 (s, 3H) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 5: Preparation of 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)benzonitrile (19)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 19 |
|
Yellow solid | Ex 5 |
| 20 |
|
Amber solid | Ex 5 |
| 21 |
|
Brown oil | Ex 5 |
| 22 |
|
Brown Oil | Ex 5 |
| 23 |
|
Yellow oil | Ex 5 |
| Compoun d No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 19 | 387 ([M+H]+) | (300 MHz, CDCl3) δ 8.36 (d, J = 2.7 Hz, 1H), 8.15 - 8.02 (m, 1H), 7.86 (d, J = 8.7 Hz, 1H), 7.74 - 7.65 (m, 2H), 7.53 (dd, J = 8.6, 2.7 Hz, 1H), 7.16 - 7.06 (m, 2H), 7.05 - 6.96 (m, 1H), 6.84 (ddd, J = 10.9, 8.6, 2.4 Hz, 1H) | 19F NMR (376 MHz, CDCl3) δ - 99.13 (d, J = 13.5 Hz), -100.67 (d, J = 14.9 Hz), - 101.82 (dd, J = 28.5, 14.2 Hz) | ||
| 20 | 368 ([M+H]+) | 8.29 (d, J = 2.8 Hz, 1H), 8.04 (td, J = 8.4, 6.4 Hz, 1H), 7.81 (d, J = 8.6 Hz, 1H), 7.44 (dd, J = 8.7, 2.9 Hz, 1H), 6.99 (dddd, J = 8.7, 7.6, 2.4, 0.9 Hz, 1H), 6.82 (ddd, J = 11.0, 8.6, 2.4 Hz, 1H), 4.45 (q, J = 7.8 Hz, 2H) | |||
| 21 | 431 ([M+H]+) | 8.53 - 8.37 (m, 1H), 8.09 (td, J = 8.4, 6.6 Hz, 1H), 8.05 - 7.97 (m, 1H), 7.90 (d, J = 8.5 Hz, 1H), 7.76 (dd, J = 8.6, 2.6 Hz, 1H), 7.15 (d, J = 8.6 Hz, 1H), 7.05 - 6.90 (m, 1H), 6.84 (ddd, J = 11.0, 8.7, 2.4 Hz, 1H) | |||
| 22 | 396 ([M]+) | 8.44 (dd, J = 2.6, 0.7 Hz, 1H), 8.12 - 8.03 (m, 2H), 7.86 (dd, J = 8.6, 0.7 Hz, 1H), 7.72 (ddd, J = 8.7, 4.4, 2.6 Hz, 2H), 7.04 - 6.96 (m, 2H), 6.84 (ddd, J = 11.0, 8.7,2.4 Hz, 1H) | |||
| 23 | 352 ([M+H]+) | 8.51 (s, 1H), 8.08 (m, 1H), 7.88 (dd, J = 8.2, 1.7 Hz, 1H), 7.84 (dd, J = 8.1, 0.9 Hz, 1H), 7.00 (m, 1H), 6.83 (ddd, J = 10.8, 8.6, 2.4 Hz, 1H), 3.46 (q, J = 10.4 Hz, 2H) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 6. Preparation of 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-oxoethyl)pyridin-3-yl)oxy)benzonitrile (19)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 19 |
|
Yellow solid | Ex 6 |
| 25 | Br | White solid | Ex 6 |
| Compou nd No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 25 | 349 ([M+1]+) | 8.67 - 8.58 (m, 1H), 8.10 - 7.99 (m, 2H), 7.73 (dd, J = 8.4, 0.4 Hz, 1H), 7.05 - 6.94 (m, 1H), 6.83 (ddd, J = 10.7, 5.5, 1.4 Hz, 1H) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 7. Preparation of 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-nitropropyl)pyridin-3-yl)oxy)benzonitrile (26)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 26 |
|
White solid | Ex 7, Methods A and B |
| 27 |
|
Tan solid | Ex 7, Method B |
| 28 |
|
Vanilla color solid | Ex 7, Method B |
| 29 |
|
Black oil | Ex 7, Method B |
| 30 | Br | White solid | Ex 7, Method A |
| 31 |
|
Solid | Ex 7, Method B |
| Compound No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 26 | 448 ([M+H]+) | (300 MHz, CDCl3) δ 8.40 (d, J = 2.7 Hz, 1H), 7.71 (m, 2H), 7.54 (m, 2H), 7.41 (dd, J = 8.7, 2.7 Hz, 1H), 7.10 (m, 2H), 6.83 (m, 2H), 6.16 (s, 1H), 5.63 (d, J = 12.7 Hz, 1H), 5.10 (dd, J = 12.7, 1.7 Hz, 1H) | 3337, 2229 | ||
| 27 | 429 ([M+H]+) | 8.35 (d, J = 2.9 Hz, 1H), 7.57 - 7.45 (m, 2H), 7.32 (dd, J = 8.8, 2.9 Hz, 1H), 6.87 - 6.75 (m, 2H), 6.36 (s, 1H), 5.62 (d, J = 12.6 Hz, 1H), 5.06 (dd, J = 12.6, 1.6 Hz, 1H), 4.45 (q, J = 7.8 Hz, 2H) | 19F NMR (376 MHz, CDCl3) δ - 78.68 (br), -104.97 (dd, J = 255.68, 15.04 Hz), -105.54 (m), -108.44 (d, J = 7.52 Hz), - 109.49 (dd, J = 255.68, 15.04 Hz) | ||
| 28 | 492 ([M+1]+) | 8.53 (d, J = 2.5 Hz, 1H), 8.41 (dd, J = 1.5, 0.8 Hz, 1H), 8.00 (dd, J = 8.6, 2.4 Hz, 1H), 7.68 (dd, J = 8.6, 2.6 Hz, 1H), 7.63 -7.51 (m, 2H), 7.16 (d, J = 8.7 Hz, 1H), 6.94 - 6.79 (m, 2H), 6.48 (s, 1H), 5.66 (d, J = 12.6 Hz, 1H), 5.09 (dd, J = 12.6, 1.1 Hz, 1H) | 19F NMR (376 MHz, CDCl3) δ - 104.97 (d, J = 19.7 Hz), -105.43 - 105.73 (m), - 108.53 (d, J = 9.0 Hz), -108.76 - 109.77 (m), 61.82 (s) | ||
| 29 | 457 ([M]+) | 8.50 (d, J = 2.6 Hz, 1H), 8.15 - 8.06 (m, 1H), 7.75 (dd, J = 8.7, 2.6 Hz, 1H), 7.64 (dd, J = 8.6, 2.6 Hz, 1H), 7.57 (dd, J = 8.7, 0.8 Hz, 2H), 7.02 (dd, J = 8.7, 0.6 Hz, 1H), 6.89 - 6.78 (m, 2H), 6.57 (s, 1H), 5.64 (d, J = 12.5 Hz, 1H), 5.14 - 5.00 (m, 1H) | |||
| 30 | 409 ([M]+) | 8.68 (d, J = 2.2 Hz, 1H), 7.94 (dd, J = 8.4, 2.2 Hz, 1H), 7.53 - 7.45 (m, 1H), 7.41 (d, J = 8.4 Hz, 1H), 6.87 - 6.77 (m, 2H), 5.93 (s, 1H), 5.65 (d, J = 12.8 Hz, 1H), 5.08 (dd, J = 12.8, 1.7 Hz, 1H) | 19F NMR (376 MHz, CDCl3) δ - 105.51 (ddd, J = 30.0, 17.6, 9.5 Hz), -106.02 (dd, J = 258.3, 17.4 Hz), -108.03 (d, J = 9.5 Hz), -110.56 (dd, J = 258.2, 30.5 Hz) | ||
| 31 | 413 ([M+H]+) | 8.56 (s, 1H), 7.78 (dd, J = 8.1, 1.6 Hz, 1H), 7.51 (m, 2H), 6.81 (m, 2H), 6.40 (s, 1H), 5.64 (d, J = 12.6 Hz, 1H), 5.08 (dd, J = 12.6, 1.4 Hz, 1H), 3.46 (q, J = 10.3 Hz, 2H) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 8. Preparation of 4-((6-(3-amino-2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxypropyl)pyridin-3-yl)oxy)benzonitrile (32)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 32 |
|
Faint yellow foam | Ex 8, Methods A, B and C |
| 33 |
|
Oil | Ex 8, Method C |
| 34 |
|
Light brown oil | Ex 8, Method C |
| 35 |
|
Light Yellow solid | Ex 8, Method C |
| 36 | Br | Colorless oil | Ex 8, Method A |
| 37 |
|
Nearly white solid | Ex 8, Method C |
| Comp ound No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 32 | 418 ([M+H]+) | (300 MHz, CDCl3) δ 8.36 (d, J = 2.6 Hz, 1H), 7.67 (m, 2H), 7.50 (m, 1H), 7.44 (app d, J = 8.6 Hz, 1H), 7.36 (dd, J = 8.6, 2.7 Hz, 1H), 7.05 (m, 2H), 6.76 (m, 2H), 3.84 (dd, J = 13.7, 4.2 Hz, 1H), 3.21 (d, J = 13.5 Hz, 1H), 2.47 (br s, 2H) | 3419, 3076, 2228 | ||
| 33 | 8.31 (d, J = 2.9 Hz, 1H), 7.50 (td, J = 8.7, 6.6 Hz, 1H), 7.39 (d, J = 8.7 Hz, 1H), 7.29 - 7.21 (m, 1H), 6.76 (dddd, J = 14.3, 11.5, 8.5, 2.6 Hz, 2H), 6.29 (s, 1H), 4.43 (q, J = 7.9 Hz, 2H), 3.79 (dd, J = 13.6, 4.4 Hz, 1H), 3.22 (d, J = 13.8 Hz, 1H), 1.44 - 1.07 (m, 2H) | ||||
| 34 | 460 ([M-1]-) | 8.48 (d, J = 2.5 Hz, 1H), 8.41 (dd, J = 1.6,0.8 Hz, 1H), 8.02 - 7.92 (m, 1H), 7.62 - 7.47 (m, 3H), 7.13 (d, J = 8.6 Hz, 1H), 6.88-6.72 (m, 2H), 6.35 - 6.33 (m, 1H), 3.80 (dd, J = 13.7, 4.2 Hz, 1H), 3.26 (d, J = 13.7 Hz, 1H), 0.9 - 1.6 (br, 2H) | |||
| 35 | 457 ([M]+) | 8.45 (d, J = 2.7 Hz, 1H), 8.09 (dd, J = 2.6, 0.7 Hz, 1H), 7.72 (dd, J = 8.7, 2.6 Hz, 1H), 7.62 - 7.53 (m, 2H), 7.49 (dd, J = 8.6, 0.7 Hz, 1H), 6.99 (dd, J = 8.7, 0.7 Hz, 1H), 6.79 (dddd, J = 20.5, 11.5, 8.7, 2.4 Hz, 2H), 5.30 (s, 2H), 3.83 - 3.63 (m, 1H), 3.28 (d, J = 12.6 Hz, 1H), 1.47 (s, 1H) | |||
| 36 | 379 ([M]+) | 8.62 (dd, J = 7.0, 2.1 Hz, 1H), 7.85 (dd, J = 8.4, 2.3 Hz, 1H), 7.52 - 7.41 (m, 1H), 7.30 (dd, J = 8.4, 0.5 Hz, 1H), 6.84 - 6.68 (m, 2H), 3.87 (dd, J = 13.7, 4.7 Hz, 1H), 3.19 (d, J = 13.7 Hz, 1H), 1.0 - 1.9 (br, 2H), 0.8 - 0.9 (br, 1H) | 19F NMR (376 MHz, CDCl3) δ - 106.15 (ddd, J = 23.2, 15.0, 8.3 Hz), -109.39 (dd, J = 252.1, 23.3 Hz), -110.47 (d, J = 8.8 Hz), - 110.99 (dd, J = 252.2, 14.9 Hz) | ||
| 37 | 383 ([M+H]+) | 8.53 - 8.49 (m, 1H), 7.69 (dd, J = 8.1, 2.1 Hz, 1H), 7.55 - 7.41 (m, 2H), 6.82 - 6.70 (m, 2H), 3.80 (dd, J = 13.6, 4.4 Hz, 1H), 3.43 (q, J = 10.5 Hz, 2H), 3.23 (dq, J = 13.8, 1.1 Hz, 1H) | 19F NMR -65.75 (s, 3F), ABX: X = - 106.29 (ddd, J = 22.0, 15.9, 8.6 Hz, IF), B = - 109.27 (JAB = 254.7 Hz, JBX = 21.9 Hz, IF), - 110.61 (d, J = 8.4 Hz, IF), A = - 111.04 (JAB = 254.7, JAX = 15.9 Hz, 1F) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
Example 9. Preparation of 4-((6-(2-(2,4-difluorophenyl)-1,1-difluoro-2-hydroxy-3-(1H-tetrazol-1-yl)propyl)pyridin-3-yl)oxy)benzonitrile (38)
| Compound No. | R1 | Appearance | Prepared as in Example(s): |
| 38 |
|
off-white solid | Ex 9, Methods A and B |
| 39 |
|
Foam | Ex 9, Method B |
| 40 |
|
Pink colored foam | Ex 9, Method B |
| 41 |
|
Dark yellow solid | Ex 9, Method B |
| 42 | Br | Light brown thick oil | Ex 9, Method A |
| 43 |
|
Slightly yellowed glass | Ex 9, Method B |
| Compound No. | Mp (°C) | ESIMS m/z | 1H NMR (δ)a | 13C NMR or 19F NMR (δ) | IR(thin film) cm-1 |
| 38 | 469 ([M-H]-) | (300 MHz, CDCl3) δ 8.74 (s, 1H), 8.26 (d, J = 2.7 Hz, 1H), 7.71 (m, 2H), 7.62 (d, J = 8.7 Hz, 1H), 7.43 (m, 2H), 7.19 (s, 1H), 7.12 (m, 2H), 6.76 (m, 2H), 5.44 (d, J = 14.4 Hz, 1H), 5.23 (dd, J = 14.4, 1.5 Hz, 1H) | 19F NMR (376 MHz, CDCl3) δ -104.05 (m), -105.67 (dd, J = 263.9, 20.1 Hz),-107.32 (dd, J = 264.1, 34.3 Hz), - 107.83 (d, J = 9.6 Hz) | ||
| 39 | 452 ([M+H]+) | 8.75 (s, 1H), 8.27 (d, J = 2.9 Hz, 1H), 7.57 (d, J = 8.8 Hz, 1H), 7.36 - 7.28 (m, 2H), 7.26 (s, 1H), 6.76 (ddd, J = 12.0, 8.5, 2.6 Hz, 1H), 6.71- 6.62 (m, 1H), 5.57 (dd, J = 14.3, 0.8 Hz, 1H), 5.12 (dd, J = 14.3, 1.5 Hz, 1H), 4.44 (q, J = 7.8 Hz, 2H) | 19F NMR (376 MHz, CDCl3) δ -73.68 (m), -103.79 (dd, J = 263.2, 41.46 Hz), - 104.93 (m), 108.00 (d, J = 11.28 Hz), - 110.45 (dd, J = 263.2, 41.46 Hz) | ||
| 40 | 515 ([M+H]+) | 8.79 (s, 1H), 8.48 (d, J = 2.4 Hz, 1H), 8.41 (dd, J = 1.6, 0.8 Hz, 1H), 8.01 (dd, J = 8.6, 2.4 Hz, 1H), 7.68 (dt, J = 18.4, 5.5 Hz, 2H), 7.37 (td, J = 8.9, 6.5 Hz, 2H), 7.17 (d, J = 8.6 Hz, 1H), 6.82 - 6.72 (m, 1H), 6.72-6.62 (m, 1H), 5.64 (d, J = 14.3 Hz, 1H), 5.13 (d, J = 14.4 Hz, 1H) | |||
| 41 | 61-63 | 480 ([M]+) | 8.76 (s, 1H), 8.53 - 8.39 (m, 1H), 8.09 (dd, J = 2.7, 0.7 Hz, 1H), 7.75 (dd, J = 8.7, 2.6 Hz, 1H), 7.71 - 7.53 (m, 2H), 7.35 (td, J = 8.9, 6.4 Hz, 1H), 7.02 (dd, J = 8.7, 0.7 Hz, 1H), 6.77 (ddd, J = 12.0, 8.5, 2.6 Hz, 1H), 6.72 - 6.66 (m, 1H), 5.68 - 5.58 (m, 1H), 5.14 - 5.07 (m, 1H), 2.10 (s, 1H) | ||
| 42 | 432.11 ([M]+) | 8.76 (s, 1H), 8.63 (d, J = 1.4 Hz, 1H), 7.95 (dd, J = 8.4, 2.2 Hz, 1H), 7.46 (d, J = 8.4 Hz, 1H), 7.34 - 7.23 (m, 1H), 6.93 (s, 1H), 6.81 - 6.72 (m, 1H), 6.72 - 6.62 (m, 1H), 5.61 (d, J = 14.3 Hz, 1H), 5.12 (d, J = 14.8 Hz, 1H) | 19F NMR (376 MHz, CDCl3) δ -103.52 -- 103.97 (m), -103.96 --104.40(m), - 107.62 (d, J = 9.7 Hz), -112.16 (dd, J = 263.2, 43.0 Hz) | ||
| 43 | 436 ([M+H]+) | 8.76 (s, 1H), 8.49 (d, J = 2.0 Hz, 1H), 7.79 (dd, J = 8.1, 2.1 Hz, 1H), 7.60 (d, J = 8.1 Hz, 1H), 7.37 - 7.28 (m, 2H), 6.76 (ddd, J = 12.1, 8.5, 2.6 Hz, 1H), 6.65 (dddd, J = 8.7, 7.5, 2.6, 0.9 Hz, 1H), 5.59 (dd, J = 14.3, 0.9 Hz, 1H), 5.13 (dd, J = 14.1, 1.4 Hz, 1H), 3.45 (q, J = 10.3 Hz, 2H) | 19F NMR (376 MHz, CDCl3) δ -65.61 (s, 3F), ABX: X= - 103.93 (ddd, JAX = 41.9 Hz, JAB = 15.4, 9.8 Hz, IF), B = - 104.75 (JAB = 262.9 Hz, JBX = 15.5 Hz, IF), -107.91 (d, J = 9.7 Hz, IF), A = - 111.65 (JAB = 262.9 Hz, JAX = 41.6 Hz, 1F) |
| aAll 1H NMR data measured in CDCl3 at 400 MHz unless otherwise noted |
contacting compounds of Formula IIa with a preformed organometallic reagent,
to afford compounds of Formula III, or salts thereof;
wherein R1 is
or Br;
wherein R2 and R3 are selected from -OCH3, -CH3, -CH2CH3 or joined together to form a morpholine ring; preferably
wherein the preformed organometallic reagent is formed by a metal halogen exchange reaction of 1-bromo-2,4-difluorobenzene with one of magnesium, n-butyllithium, and isopropylmagnesium chloride; or
wherein the step of contacting compounds of Formula IIa with the preformed organometallic reagent further includes an aprotic solvent; or
wherein the aprotic solvent is one of diethyl ether and tetrahydrofuran; or wherein the step of contacting compounds of Formula IIa with the preformed organometallic reagent is carried out at 0°C.
contacting compounds of the Formula I with ethyl 2-bromo-2,2-difluoroacetate and a
metal,
to afford compounds of Formula II; preferably
wherein the metal is copper; or
wherein the step of contacting I with ethyl 2-bromo-2,2-difluoroacetate and a metal further includes a solvent; or
wherein the step of contacting I with ethyl 2-bromo-2,2-difluoroacetate and a metal further includes a solvent selected from dimethyl sulfoxide, dimethylformamide, and mixtures thereof.
contacting 6-bromopyridin-3-ol with one of 2,2,2-trifluoroethyl trifluoromethanesulfonate, 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine to afford compounds of Formula I; preferably
wherein the step of contacting 6-bromopyridin-3-ol with one of 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine further includes a base; or
wherein the step of contacting 6-bromopyridin-3-ol with one of 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine further includes a base that is one of cesium carbonate and potassium carbonate; or
wherein the step of contacting 6-bromopyridin-3-ol with one of 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine further includes a solvent; or
wherein the step of contacting 6-bromopyridin-3-ol with one of 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine further includes a solvent that is one of dimethyl sulfoxide and dimethylformamide; or
wherein the step of contacting 6-bromopyridin-3-ol with one of 5-chloro-2-fluoropyridine and 2-fluoro-5-(trifluoromethyl)pyridine is carried out between 65°C and 100 °C.
R1 is
or Br;
R2 is ethoxy; 2,4-difluorophenyl; -N(OCH3)(CH3); -N(CH3)(CH3); - N(CH2CH3)(CH2CH3); or
R3 is -OH;
R4 is nitromethyl or aminomethyl;
alternatively R3 and R4 may be taken together to form a carbonyl.R1 is
or Br;
R2 is 2,4-difluorophenyl;
R3 is -OH;
R4 is nitromethyl or aminomethyl.
R1 is
or Br;
R2 is -N(OCH3)(CH3); -N(CH3)(CH3); -N(CH2CH3)(CH2CH3); or
and
R3 and R4 are taken together to form a carbonyl.
das Inkontaktbringen von Verbindungen der Formel IIa mit einem zuvor gebildeten organometallischen
Reagens,
um Verbindungen der Formel III oder Salze davon zu ergeben;
wobei gilt: R1 ist
oder Br;
wobei gilt: R2 und R3 sind ausgewählt aus -OCH3, -CH3, -CH2CH3 oder sind miteinander verbunden, um einen Morpholinring zu bilden; bevorzugt
wobei gilt: das zuvor gebildete organometallische Reagens ist gebildet durch eine Metallhalogenaustauschreaktion von 1-Brom-2,4-difluorbenzol mit einem von Magnesium, n-Butyllithium und Isopropylmagnesiumchlorid; oder
wobei gilt: die Stufe des Inkontaktbringens von Verbindungen der Formel IIa mit dem zuvor gebildeten organometallischen Reagens umfasst des Weiteren ein aprotisches Lösungsmittel; oder
wobei gilt: das aprotische Lösungsmittel ist eines von Diethylether und Tetrahydrofuran; oder
wobei gilt: die Stufe des Inkontaktbringens von Verbindungen der Formel IIa mit dem zuvor gebildeten organometallischen Reagens wird bei 0°C durchgeführt.
das Inkontaktbringen der Formel II mit einem Amin, einer Lewis-Säure und einem Lösungsmittel
um Verbindungen der Formel IIa zu ergeben; bevorzugt
wobei gilt: das Amin ist ausgewählt aus N,O-Dimethylhydroxylamin, Dimethylamin, Diethylamin und Morpholin; oder
wobei gilt: die Lewis-Säure ist Dimethylaluminiumchlorid; oder
wobei gilt: das Lösungsmittel ist Dichlormethan; oder
wobei gilt: die Stufe des Inkontaktbringens von Verbindungen der Formen II mit dem Amin, der Lewis-Säure und dem Lösungsmittel wird durchgeführt in einer solchen Weise, dass die Temperatur unterhalb von 15°C gehalten wird.
das Inkontaktbringen von Verbindungen der Formel I mit Ethyl-2-brom-2,2-difluoracetat
und einem Metall,
um Verbindungen der Formel II zu ergeben; bevorzugt
wobei gilt: das Metall ist Kupfer; oder
wobei gilt: die Stufe des Inkontaktbringens von I mit Ethyl-2-brom-2,2-difluoracetat und einem Metall umfasst des Weiteren ein Lösungsmittel; oder
wobei gilt: die Stufe des Inkontaktbringens von I mit Ethyl-2-brom-2,2-difluoracetat und einem Metall umfasst des Weiteren ein Lösungsmittel, ausgewählt aus Dimethylsulfoxid, Dimethylformamid und Gemischen davon.
das Inkontaktbringen von 6-Brompyridin-3-ol mit einem von 2,2,2-Trifluorethyltrifluormethansulfonat, 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin, um Verbindungen der Formel I zu ergeben; bevorzugt
wobei gilt: die Stufe des Inkontaktbringens von 6-Brompyridin-3-ol mit einem von 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin umfasst des Weiteren eine Base; oder
wobei gilt: die Stufe des Inkontaktbringens von 6-Brompyridin-3-ol mit einem von 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin umfasst des Weiteren eine Base, die eines von Cäsiumcarbonat und Kaliumcarbonat ist; oder
wobei gilt: die Stufe des Inkontaktbringens von 6-Brompyridin-3-ol mit einem von 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin umfasst des Weiteren ein Lösungsmittel; oder
wobei gilt: die Stufe des Inkontaktbringens von 6-Brompyridin-3-ol mit einem von 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin umfasst des Weiteren ein Lösungsmittel, das eines von Dimethylsulfoxid und Dimethylformamid ist; oder
wobei gilt: die Stufe des Inkontaktbringens von 6-Brompyridin-3-ol mit einem von 5-Chlor-2-fluorpyridin und 2-Fluor-5-(trifluormethyl)pyridin wird durchgeführt zwischen 65°C und 100°C.
R1 ist
oder Br;
R2 ist Ethoxy; 2,4-Difluorphenyl; -N(OCH3)(CH3); -N(CH3)(CH3); -N(CH2CH3)(CH2CH3); oder
R3 ist -OH;
R4 ist Nitromethyl oder Aminomethyl;
alternative können R3 uand R4 zusammengenommen sein, um ein Carbonyl zu bilden;
R1 ist
oder Br;
R2 ist 2,4-Ddifluorphenyl;
R3 ist -OH;
R4 ist Nitromethyl oder Aminomethyl.
R1 ist
oder Br;
R2 ist -N(OCH3)(CH3); -N (CH3)(CH3); -N (CH2CH3)(CH2CH3); oder
und
R3 und R4 sind zusammengenommen, um ein Carbonyl zu bilden.
mettre en contact des composés de formule IIa avec un réactif organométallique préformé,
pour obtenir des composés de Formule III, ou des sels de ceux-ci ;
dans lequel R1 représente
ou Br;
où R2 et R3 sont choisis parmi -OCH3, -CH3, -CH2CH3 ou sont reliés ensemble pour former un cycle morpholine ; de préférence
dans lequel le réactif organométallique préformé est formé par une réaction d'échange d'halogène métallique de 1-bromo-2,4-difluorobenzène avec un des éléments suivants : magnésium, n-butyllithium et chlorure d'isopropylmagnésium ; ou
dans lequel l'étape consistant à mettre en contact des composés de formule IIa avec le réactif organométallique préformé comprend en outre un solvant aprotique ; ou
dans lequel le solvant aprotique est un des éléments suivants : éther diéthylique et tétrahydrofuranne ; ou
dans lequel l'étape consistant à mettre en contact des composés de formule IIa avec le réactif organométallique préformé est effectuée à 0 °C.
mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 2,2,2-trifluoroéthyl trifluorométhanesulfonate, 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine pour obtenir des composés de formule I ; de préférence
dans lequel l'étape consistant à mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine, comprend en outre une base ; ou
dans lequel l'étape consistant à mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine, comprend en outre une base qui est un des éléments suivants : carbonate de césium et carbonate de potassium ; ou
dans lequel l'étape consistant à mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine, comprend en outre un solvant ; ou
dans lequel l'étape consistant à mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine, comprend en outre un solvant qui est un des éléments suivants : diméthylsulfoxyde et diméthylformamide ; ou
dans lequel l'étape consistant à mettre en contact du 6-bromopyridin-3-ol avec un des éléments suivants : 5-chloro-2-fluoropyridine et 2-fluoro-5-(trifluorométhyl)pyridine est effectuée entre 65 °C et 100 °C.
R1 représente
ou Br ;
R2 représente un groupe éthoxy; 2,4-difluorophényl ; -N(OCH3)(CH3) ; - N(CH3)(CH3); -N(CH2CH3)(CH2CH3); ou
R3 représente -OH ;
R4 représente un nitrométhyle ou un aminométhyle ; alternativement R3 et R4 peuvent être pris ensemble pour former un carbonyle.
R1 représente
ou Br ;
R2 représente le 2,4-difluorophényle ;
R3 représente -OH ;
R4 représente un groupe nitrométhyle ou aminométhyle.
R1 représente
ou Br ;
R2 représente -N(OCH3)(CH3); -N(CH3)(CH3); -N(CH2CH3)(CH2CH3); ou
et
R3 et R4 sont pris ensemble pour former un carbonyle.
REFERENCES CITED IN THE DESCRIPTION
Patent documents cited in the description